HeraMED (STU:1I4) Beta: 1.2756 (As of Jun. 29, 2026)


What is HeraMED Beta?

HeraMED STU:1I4 +5.00% Beta is 1.2756 as of Jun. 29, 2026. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-29), HeraMED's Beta is 1.2756.

HeraMED  (STU:1I4) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

HeraMED Beta Related Terms

HeraMED Beta Historical Data

* Premium members only.

The historical data trend for HeraMED's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeraMED Beta Chart

HeraMED Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.06 2.57 -0.70 -0.94

HeraMED Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.57 2.18 -0.70 1.56 -0.94

STU:1I4 vs ABT, SYK, MDT: Beta Comparison

For the Medical Devices subindustry, HeraMED's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HeraMED Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, HeraMED's Beta distribution charts can be found below:

* The bar in red indicates where HeraMED's Beta falls into.


HeraMED Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.2756 mean?
HeraMED (STU:1I4) has a Beta of 1.2756 as of Jun. 29, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for HeraMED and its competitors.
Is HeraMED's Beta too high?
HeraMED's current Beta is 1.2756.
How does HeraMED's Beta compare to ABT and SYK?
HeraMED's Beta of 1.2756 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for HeraMED and its competitors. HeraMED's current Beta is 1.2756. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeraMED stock overvalued right now?
Based on GuruFocus' analysis, HeraMED (STU:1I4) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.02 — trading 110% above its estimated fair value. The current Beta is 1.2756. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For HeraMED (STU:1I4), the current Beta is 1.2756 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HeraMED Business Description

Other Exchanges 1I4:GermanyHMD:Australia
Address 117 Camberwell Road, Level 1 - Suite 1, Hawthorn East, Melbourne, VIC, AUS, 3123
HeraMED Ltd is a medical data and technology company providing the digital transformation of maternity care by revolutionizing the prenatal and postpartum experience with its hybrid maternity care platform. It offers a proprietary platform that utilizes hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence. Its offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, and allow healthcare professionals to provide the care and enable early detection and prevention of potential risks.